List of Excipients in Branded Drug LEVAQUIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	LEVAQUIN	levofloxacin	21695-464	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	LEVAQUIN	levofloxacin	21695-464	CROSPOVIDONE
Rebel Distributors Corp	LEVAQUIN	levofloxacin	21695-464	FERRIC OXIDE RED
Rebel Distributors Corp	LEVAQUIN	levofloxacin	21695-464	FERRIC OXIDE YELLOW

Generic Drugs Containing LEVAQUIN

Company	Ingredient	NDC	Excipient
DIRECT RX	levofloxacin	61919-359	CELLULOSE, MICROCRYSTALLINE
DIRECT RX	levofloxacin	61919-359	CROSPOVIDONE
DIRECT RX	levofloxacin	61919-359	FERRIC OXIDE RED
DIRECT RX	levofloxacin	61919-359	HYPROMELLOSES

What are the Most Frequently-Used Excipients in LEVAQUIN?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	FERRIC OXIDE RED
1	HYPROMELLOSES

Levaquin Excipient Strategy and Commercial Opportunities for Levofloxacin

Last updated: July 31, 2026

Levaquin, the branded form of levofloxacin, is a mature fluoroquinolone product with limited branded patent value and substantial generic competition. The commercial opportunity is no longer centered on basic molecule ownership. It lies in dosage-form optimization, excipient control, hospital-use convenience, stability, taste masking, packaging, and differentiated delivery.

Levofloxacin is marketed in oral tablets, an oral solution, and intravenous formulations. The most important excipient issue is avoiding formulation components that reduce absorption through chelation or complexation with the active ingredient. Products containing aluminum, magnesium, calcium, iron, or other multivalent cations can reduce oral levofloxacin exposure and require administration separation under FDA labeling.[1]

What is Levaquin and how is levofloxacin formulated?

Levaquin is the hemihydrate form of levofloxacin, the S-enantiomer of ofloxacin. FDA-approved dosage forms include:

Dosage form	Representative strength	Principal commercial use	Key excipient priorities
Immediate-release tablet	250 mg, 500 mg, 750 mg	Outpatient systemic infection treatment	Rapid dissolution, low cation content, tablet robustness
Oral solution	25 mg/mL	Patients unable to swallow tablets	Taste masking, chemical stability, preservative system
Intravenous solution	5 mg/mL	Hospital and infusion use	Sterility, particulate control, container compatibility
Premixed IV bags	Commonly 250 mL or 150 mL presentations	Hospital pharmacy and bedside administration	Ready-to-use handling, oxygen and light protection, low overfill variability

The reference product labeling identifies inactive ingredients such as crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, titanium dioxide, and other tablet-specific materials depending on strength and presentation.[1] The presence of magnesium stearate in a compressed tablet does not create the same exposure concern as orally administered magnesium antacids because the excipient is used at a low level and is not intended to deliver a soluble cation dose. Formulators must still evaluate dissolution, assay, impurity formation, and local regulatory expectations.

What excipient strategy best fits generic levofloxacin tablets?

The highest-volume generic opportunity is an immediate-release tablet using conventional, low-cost excipients. A viable formulation strategy should prioritize:

1. Rapid and reproducible dissolution.
2. Low tablet weight.
3. Mechanical strength during high-volume packaging and distribution.
4. Minimal moisture uptake.
5. Robust content uniformity across 250 mg, 500 mg, and 750 mg strengths.
6. Avoidance of excipients that introduce clinically relevant multivalent cation exposure.

Direct-compression strategy

A direct-compression tablet can use microcrystalline cellulose, crospovidone or croscarmellose sodium, colloidal silicon dioxide, and a lubricant such as magnesium stearate. The approach reduces processing steps and is attractive for mature generic products.

The main risks are poor powder flow, segregation, high lubricant sensitivity, and slower dissolution if excessive compression force or lubricant concentration is used. Levofloxacin tablets must meet immediate-release dissolution expectations without relying on an unusually aggressive disintegrant load.

Wet-granulation strategy

Wet granulation can improve flow and content uniformity when the API has poor bulk density or segregation behavior. It introduces additional water, heat, and drying exposure. The process must control hydrate conversion, impurity growth, granule hardness, and residual moisture.

Wet granulation is commercially relevant when a manufacturer needs to use existing high-throughput tablet equipment or achieve tighter uniformity than direct compression provides. It is less attractive where the API shows sensitivity to moisture or where manufacturing simplicity is a priority.

Dry-granulation strategy

Roller compaction offers a middle ground. It avoids water while improving flow and reducing segregation. The principal formulation risks are excessive ribbon density, slow disintegration, and variability in granule size.

A dry-granulated levofloxacin tablet can support a differentiated manufacturing dossier if it produces a materially better impurity profile, higher throughput, or lower solvent and energy use. Process value alone may not create strong patent protection, but it can improve cost of goods and supply reliability.

Which excipients create the greatest levofloxacin compatibility risk?

The principal clinical formulation concern is cation-mediated reduction in oral absorption.

Multivalent cations and chelation

Levofloxacin can form complexes with aluminum, magnesium, calcium, iron, and other metal ions. The FDA label instructs patients to take levofloxacin at least two hours before or two hours after antacids containing magnesium or aluminum, sucralfate, didanosine buffer systems, and products containing iron or zinc.[1]

This has several formulation implications:

Excipient or product component	Risk	Commercial implication
Calcium salts	Potential reduction in oral exposure through complexation	Avoid unnecessary calcium-containing oral excipient systems
Magnesium salts	Potential reduction in oral exposure	Avoid soluble magnesium-based excipients where possible
Aluminum salts	Potential reduction in oral exposure	Relevant to antacid-like and suspension systems
Iron salts	Strong complexation risk	Avoid in combination products unless clinically justified
Zinc salts	Potential absorption interaction	Relevant to nutritional or pediatric products
Magnesium stearate	Generally used as a low-level lubricant	Evaluate dissolution and compatibility, but distinguish from soluble magnesium salts
Calcium phosphate	May contribute to cation exposure	Requires formulation-specific dissolution and bioavailability assessment

The commercial lesson is direct: an oral levofloxacin product should not be differentiated by adding mineral excipients unless the sponsor has a clear clinical and regulatory rationale.

Lubricants and dissolution

Magnesium stearate is common in tablet manufacturing, but excessive levels or prolonged blending can create hydrophobicity and slow dissolution. This risk is manageable through lubricant concentration, blend time, particle-size control, and compression-force optimization.

Alternative lubricants may include sodium stearyl fumarate or stearic acid. Each alternative can affect tablet ejection, dissolution, stability, and equipment behavior. Substitution is commercially useful only when it solves a measurable problem, such as faster dissolution, reduced sticking, or improved stability.

Polymers and disintegrants

Crospovidone, croscarmellose sodium, and sodium starch glycolate are conventional choices. Selection should reflect the desired disintegration profile, API particle size, compression conditions, and storage humidity.

A superdisintegrant-based formulation may be attractive for high-dose 750 mg tablets, where tablet mass and dissolution can become more difficult to manage. A smaller tablet with equivalent bioavailability can support patient convenience but may require stronger compression and more efficient disintegration.

What excipient strategy is appropriate for levofloxacin oral solution?

Levofloxacin oral solution has a different value proposition from tablets. The central technical problems are taste, chemical stability, microbial control, and dose-measurement accuracy.

Taste masking

Fluoroquinolones can have a pronounced bitter taste. An oral solution cannot rely on tablet coating to isolate the API. Commercial options include:

• Sweetener systems using sucrose, sorbitol, sucralose, or combinations.
• Flavor systems selected for acidic or near-neutral pH.
• Ion-pairing or complexation approaches.
• Taste-masked multiparticulates or coated particles dispersed in a liquid vehicle.
• Viscosity modification to reduce rapid tongue exposure.

A simple sweetener-and-flavor system may be adequate for adult patients but can perform poorly in pediatric or geriatric populations. High-intensity sweeteners reduce sugar load but may leave a persistent aftertaste. Polyol systems can introduce gastrointestinal tolerability concerns.

Preservatives and antimicrobial protection

An aqueous multidose product requires a validated preservative system unless packaged as a sterile single-dose product. Candidate preservatives must be assessed for:

• Compatibility with levofloxacin.
• pH dependence.
• Container adsorption.
• Microbial effectiveness.
• Pediatric acceptability.
• Regulatory status in the target jurisdiction.

The preservative system cannot be selected independently from the container closure. Plastic bottles, dosing syringes, caps, and liners may alter preservative concentration through adsorption or permeability.

pH and stability

The formulation pH affects solubility, degradation, taste, preservative efficacy, and container compatibility. A commercial formulation should establish a controlled pH range rather than relying on a broad nominal target.

Useful development tools include forced-degradation studies, photostability testing, extractables and leachables assessments, and in-use stability testing after bottle opening. A superior oral solution may compete through longer in-use stability, lower preservative burden, or more accurate dosing rather than through a new active ingredient.

What excipients are important in levofloxacin intravenous products?

The IV opportunity is concentrated in hospital efficiency, ready-to-administer packaging, and supply reliability.

Levofloxacin injection is supplied as a sterile aqueous solution. The FDA label identifies dextrose-containing presentations and other infusion configurations, with administration requirements tied to concentration and infusion time.[1] Rapid infusion can increase adverse reactions, so the delivery system must support label-compliant administration.

IV formulation priorities

Development area	Commercial objective
Ready-to-use premix	Reduce pharmacy compounding labor
Flexible bag or bottle	Improve compatibility with hospital infrastructure
Low-sorption container	Preserve delivered dose
Light and oxygen control	Limit degradation during storage
Low particulate burden	Support injectable quality requirements
Simple port configuration	Reduce preparation and administration errors
Broad temperature stability	Improve inventory management
Small-volume presentation	Support emergency and short-course use

Common excipient considerations include water for injection, dextrose or sodium chloride vehicles, pH adjustment agents, and container-closure materials. Each formulation requires evaluation of osmolality, pH, particulate matter, sterility, endotoxin, visible and subvisible particles, and compatibility with infusion sets.

Ready-to-use hospital products

A generic manufacturer can differentiate an IV product through:

• Premixed bags that eliminate dilution.
• Lower-volume presentations.
• Dual-port systems.
• Improved barcode and label design.
• Longer room-temperature stability.
• Packaging compatible with automated dispensing systems.
• Reduced overfill and more consistent extractable volume.

These attributes may not create broad composition-of-matter exclusivity, but they can support hospital contracts and reduce total treatment cost.

What patents protect Levaquin and its excipient formulations?

The original levofloxacin compound and product protection are expired in the United States. Levofloxacin is a mature small-molecule generic, and the commercial market is governed primarily by abbreviated new drug applications, manufacturing capability, quality systems, and contracting.

Orange Book status

The FDA Orange Book is the relevant source for listed patents, pediatric exclusivity, and regulatory exclusivity associated with approved products.[2] For a mature levofloxacin product, the key business issue is not an expected loss of basic patent protection. It is whether a particular generic formulation, manufacturing process, device, or use has a separate enforceable right.

Potentially relevant IP categories include:

IP category	Typical scope	Strategic value
Formulation patent	Excipient ratios, pH, release profile, taste masking	Moderate if technically narrow and difficult to design around
Process patent	Granulation, drying, impurity control, crystallization	Useful for manufacturing advantage
Packaging patent	Container, closure, or administration system	Relevant to premix and hospital products
Method-of-use patent	Specific infection, dosing regimen, or patient population	Limited for a mature broad-spectrum antibiotic
Device patent	Oral dosing system or infusion administration component	Potentially useful for differentiated products

Excipient patents are usually narrow. Their value depends on whether the claimed formulation produces a clinically or commercially meaningful advantage and whether competitors can use alternative excipients without losing bioequivalence or stability.

When did Levaquin lose exclusivity and when can generics launch?

Levofloxacin lost practical market exclusivity years ago. Generic levofloxacin products have been widely available in the United States in tablet, oral solution, and injection forms.

The relevant launch barriers are now:

1. FDA approval of the specific dosage form and strength.
2. Demonstration of bioequivalence for oral products.
3. Sterile manufacturing capability for injection.
4. Adequate impurity and stability control.
5. Procurement access through wholesalers, hospitals, group purchasing organizations, and retail pharmacies.
6. Compliance with labeling restrictions and boxed warnings.

Generic launch scenarios

Launch model	Product	Investment level	Commercial outlook
Low-cost oral generic	250/500/750 mg tablets	Low to moderate	Crowded, price-sensitive
Authorized or branded generic	Tablets or solution	Moderate	Useful for channel control
Differentiated oral solution	Taste-masked liquid	Moderate	Smaller but less commoditized
Ready-to-use IV premix	Hospital infusion	Moderate to high	Contract-driven and operationally attractive
Specialty packaging	Unit-dose or adherence-oriented format	Moderate	Depends on payer and channel acceptance
Reformulated combination	Levofloxacin with mineral or nutritional components	High	Clinically challenging because of absorption interactions

Which companies are challenging Levaquin in the generic market?

The market includes multiple generic manufacturers and contract manufacturers active in levofloxacin tablets and injection. The competitive set has historically included large generic suppliers such as Teva, Sandoz, Dr. Reddy's, Lupin, Aurobindo, Cipla, Mylan or Viatris, and other FDA-approved manufacturers, depending on dosage form and current supply status.

Competition is fragmented in tablets but more concentrated in sterile injectable products. Sterile manufacturing capacity, inspection history, fill-finish reliability, and hospital contracting are more important in IV levofloxacin than the basic tablet formulation.

A new entrant is unlikely to win with another undifferentiated 500 mg tablet. Better targets are:

• A reliable 750 mg presentation during supply interruptions.
• A palatable oral solution.
• A low-volume or ready-to-administer IV product.
• A dual-source hospital supply agreement.
• A product with improved stability in common distribution conditions.
• A formulation that minimizes tablet size without compromising dissolution.

How strong is the patent estate for levofloxacin excipient formulations?

The patent estate is weak for conventional tablet excipients and mature generic presentations. Stronger protection is possible only where the formulation has a specific technical distinction.

Stronger patent candidates

A potentially stronger formulation claim would require a defined combination of:

• Specific levofloxacin solid form or particle-size distribution.
• Narrow excipient ranges.
• A measurable dissolution or stability result.
• A defined impurity threshold after accelerated storage.
• A manufacturing step that is difficult to replicate without infringement.
• A meaningful clinical or handling benefit.

Broad claims to a levofloxacin tablet containing a conventional disintegrant, binder, lubricant, and filler are vulnerable to prior art and design-around strategies.

Weak patent candidates

Claims are generally weaker when they cover:

• Routine substitution of one filler for another.
• Standard coating systems.
• Generic flavor combinations.
• Conventional preservative selection.
• Ordinary tablet compression parameters.
• Broad lists of alternative excipients without a demonstrated effect.

For licensing purposes, a formulation patent should be evaluated against the actual commercial product, not only its claim language. A narrow patent with reliable infringement evidence may have greater value than a broad patent that is difficult to enforce.

What litigation and Paragraph IV risks affect levofloxacin?

Levofloxacin is not primarily a current patent-litigation market. The molecule is mature, multiple generic products have entered, and basic composition patents have expired.

Paragraph IV risk is more relevant when a sponsor files an ANDA against a specific listed formulation or method-of-use patent. The commercial consequences depend on:

• Whether the patent is listed in the Orange Book.
• Whether the applicant certifies Paragraph IV or uses a section viii statement.
• Whether the NDA holder files suit within the statutory period.
• Whether a 30-month stay applies.
• Whether the challenged patent covers the proposed product or only a narrow use.

A Paragraph IV strategy has limited value if the product has no meaningful remaining patent barrier or if the targeted patent can be avoided through a section viii carve-out. The largest practical risk for a new levofloxacin entrant is regulatory delay from formulation failure, not infringement exposure from the original molecule.

How does levofloxacin compare with competing antibiotics?

Levofloxacin competes with generic ciprofloxacin, moxifloxacin, ceftriaxone, azithromycin, doxycycline, and other antibacterial agents. Its commercial position is affected by antimicrobial stewardship and safety restrictions.

Product	Formulation opportunity	Key commercial constraint
Levofloxacin	Tablets, oral solution, premix IV	Fluoroquinolone safety warnings and stewardship limits
Ciprofloxacin	Tablets, suspension, IV	Strong cation interaction; broad generic competition
Moxifloxacin	Tablets and IV	More limited dosing flexibility; mature generic market
Ceftriaxone	Sterile injectable	Hospital dependence and reconstitution requirements
Azithromycin	Tablets, suspension, IV	High generic competition and cardiac safety concerns
Doxycycline	Tablets, capsules, suspension	Formulation availability and tolerability
Amoxicillin-clavulanate	Tablets, suspension	High outpatient volume and taste/stability challenges

Levofloxacin has a useful once-daily profile and broad labeled indications, but its risk profile limits unrestricted growth. The strongest commercial opportunities are operational and formulation-based rather than volume expansion through new broad indications.

What FDA regulatory issues affect levofloxacin excipient commercialization?

FDA approval requirements depend on the dosage form and the nature of the change.

Oral tablets

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. Excipient changes can affect dissolution, absorption, impurity formation, and labeling. A formulation that uses materially different excipients may require additional comparative studies or agency review.

Oral solution

Critical controls include assay uniformity, microbial limits, preservative effectiveness, in-use stability, pH, viscosity, dosing-device accuracy, and container compatibility. Taste masking must not compromise dose delivery or chemical stability.

Injectable products

Sterile products face a higher development and manufacturing burden. The sponsor must control aseptic processing, sterility assurance, endotoxins, particulate matter, container closure integrity, extractables and leachables, and infusion compatibility.

FDA labeling also contains a boxed warning for serious adverse reactions associated with systemic fluoroquinolones, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis.[1] These warnings constrain promotional positioning and reduce the value of consumer-facing excipient differentiation.

What licensing and partnership opportunities exist for levofloxacin?

Licensing opportunities are most credible in enabling technology rather than the active ingredient.

Attractive partnership targets

• Taste-masking technology for bitter oral solutions.
• Premix and flexible-bag manufacturing.
• Low-sorption or high-barrier infusion containers.
• Continuous manufacturing and dry granulation.
• Stability-enhancing packaging.
• Hospital inventory and barcode integration.
• Contract sterile manufacturing in shortage-prone markets.
• Regional rights for oral solution or IV presentations.

A licensing deal based only on a conventional excipient substitution is unlikely to command significant value. A partner will usually require evidence of improved stability, lower manufacturing cost, better patient acceptability, or procurement advantage.

What revenue exposure does levofloxacin create for manufacturers?

Levofloxacin revenue is exposed to generic price erosion, tender concentration, manufacturing interruptions, and antimicrobial stewardship. Tablet products usually have lower technical barriers and greater price competition. IV products can generate better margins when they offer dependable supply, premixed convenience, or hospital-specific packaging.

The most defensible commercial strategy is portfolio-based:

• Use tablets for baseline volume.
• Add oral solution for a less crowded niche.
• Add IV premix for hospital access.
• Protect supply with dual-site manufacturing.
• Use excipient and packaging differentiation to support contracts rather than relying on premium retail pricing.

Key Takeaways

• Levaquin is a mature levofloxacin product with limited remaining basic patent value.
• Conventional tablet excipients offer low differentiation and weak standalone patent potential.
• The principal oral formulation issue is interaction with multivalent cations, especially aluminum, magnesium, calcium, iron, and zinc.
• Taste masking, preservative systems, in-use stability, and dosing accuracy are the main oral-solution opportunities.
• Ready-to-use IV premixes, low-sorption containers, stability, and hospital workflow are the strongest injectable opportunities.
• Paragraph IV litigation is less important than regulatory execution, sterile manufacturing capacity, and procurement access.
• A commercially attractive levofloxacin product should compete through supply reliability, packaging, formulation performance, or hospital convenience.

FAQs

Can calcium phosphate be used in a levofloxacin tablet?

It may be technically possible, but the formulation requires careful evaluation because calcium can complex with levofloxacin. Soluble or readily available calcium systems create greater concern than low-solubility excipients used at low levels.

Is magnesium stearate prohibited in levofloxacin tablets?

No. Magnesium stearate is a conventional tablet lubricant. The key controls are concentration, blend time, dissolution, and compatibility. Its use should be distinguished from soluble magnesium-containing antacids.

Can a levofloxacin oral solution be positioned for pediatric use?

A pediatric oral solution requires appropriate labeling, dosing justification, palatability evidence, excipient safety assessment, and compliance with the product's approved indications and fluoroquinolone risk framework. A liquid dosage form alone does not create pediatric exclusivity.

Is a levofloxacin premix patentable?

A premix may support patent claims if it has a novel formulation, container system, stability profile, or administration configuration. A conventional solution placed in a standard infusion bag is less likely to support durable, commercially meaningful protection.

What is the best excipient opportunity for a new levofloxacin entrant?

For tablets, the best opportunity is a robust, rapidly dissolving, low-cost formulation with reliable supply. For oral liquid products, taste masking and in-use stability are more differentiated. For hospitals, ready-to-use IV packaging and sterile supply reliability offer the strongest commercial positioning.

References

1. U.S. Food and Drug Administration. (2016). Levaquin (levofloxacin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020634s069lbl.pdf

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptides. https://www.fda.gov/regulatory-information

4. U.S. Food and Drug Administration. (2022). Guidance for industry: Sterile drug products produced by aseptic processing, current good manufacturing practice. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice

5. U.S. Food and Drug Administration. (2016). Fluoroquinolone antibacterial drugs: Drug safety communication. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics-due-disabling-side-effects